Tardive dyskinesia: involuntary movement evaluation
Repeated lip, tongue, face or limb movements after dopamine-receptor-blocking medicines may need a medication review. An Ondoc clinician can discuss the symptoms and coordinate appropriate neurology or psychiatric assessment.
What your visit can cover
- Review movement onset, affected areas and exposure to dopamine-blocking medicines
- Distinguish possible tardive movements from other medication effects or neurological causes
- Plan treating-prescriber review, specialist referral and relevant treatment discussion
When to be seen in person
Trouble breathing or swallowing, sudden weakness, or new severe rigidity with fever and confusion requires emergency care. Call 911. Do not abruptly stop a prescribed antipsychotic without talking with your prescriber.
About Tardive dyskinesia
Tardive dyskinesia is a medication-associated movement disorder, not a psychiatric diagnosis. It can follow dopamine-receptor-blocking medicines such as antipsychotics and some anti-nausea drugs, and may persist after the medicine stops. Movements can involve the mouth, tongue, face, trunk or limbs. An examination and medication history help distinguish TD from tremor, akathisia, dystonia and other neurological conditions; a standardized movement assessment may be used. Treatment can include careful review of the causative medicine and a VMAT2 inhibitor. Abruptly stopping psychiatric treatment can cause relapse or worsen movements, so changes belong with the treating prescriber. Ondoc does not advertise a movement-disorder clinic or guaranteed access to a particular medicine.
MedlinePlus: Tardive dyskinesia
Additional medication information
Educational options, not an offer of a prescription from every provider. No dose or ordering instruction is provided.
- Valbenazine (Ingrezza)
- A VMAT2 inhibitor FDA-approved for tardive dyskinesia in adults. Sedation, interactions, QT effects and parkinsonism are relevant to individual review. Treatment suitability should be discussed with the treating clinician.
- Deutetrabenazine (Austedo / Austedo XR)
- A VMAT2 inhibitor FDA-approved for tardive dyskinesia in adults. Formulation, interactions and adverse effects require specialist review; Huntington-disease depression/suicidality warnings must be understood in their labeled context. No dose or fulfillment offer is provided.